

Anti-CSF1R/M-CSFR/CD115 Antibody (Cabiralizumab)

Introduction

Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and anti-tumor T cell immune responses. Cabiralizumab inhibits osteoclast activation and prevents bone destruction, and can be used in rheumatoid arthritis (RA) research.

Product parameters

Alternative Names	FPA-008, BMS-986227, ONO-4687
Target Accession	P07333
Target	CSF1R / M-CSFR / CD115
CAS number	1613144-80-1
Molecular Weight	145 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG4SP
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human CSF1R / M CSFR, Fc Tag at 2 ug/mL can bind Anti-CSF1R/M-CSFR/CD115 Antibody (Cabiralizumab), EC50=0.01383 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

